Hybrid Insulin Peptides: A New Target for Type 1 Diabetes Research

Hybrid insulin peptides represent a unique discovery in Type 1 diabetes research. They form when fragments from two different beta-cell proteins—one from proinsulin and another from a protein called chromogranin A—join together naturally in the body. This combination creates a peptide sequence that does not exist in the human genome; instead, it arises from a post-translational modification, meaning it's formed after proteins are made rather than being encoded directly by DNA.

The prototype HIP studied most extensively is called 2.5HIP, which combines a fragment of the insulin C-peptide with a natural cleavage product of chromogranin A. Researchers discovered that T cells—immune cells critical to autoimmune attack—recognize and respond to these hybrid peptides in ways that contribute to Type 1 diabetes development.

Using the nonobese diabetic (NOD) mouse model, which naturally develops Type 1 diabetes, researchers showed that hybrid insulin peptides are key targets for CD4 T cells involved in beta-cell destruction. A particularly important T-cell clone, called BDC-2.5, specifically recognizes the 2.5HIP peptide. These BDC-2.5 reactive T cells form a dominant population among immune cells that infiltrate the pancreatic islets in diabetic mice.

In a clinically significant finding, T cells reactive to HIPs are elevated in blood samples from newly diagnosed Type 1 diabetes patients and in at-risk individuals who do not yet have diabetes. This observation suggests that HIP-reactive T cells may serve as a biomarker for disease development and could help identify who is progressing toward Type 1 diabetes.

Rather than trying to eliminate HIP-reactive T cells outright, researchers explored a different approach: using HIPs themselves to teach the immune system tolerance. When 2.5HIP peptides were attached to biodegradable nanoparticles (NPs), they could induce antigen-specific immune tolerance in mouse models.

In studies using diabetic NOD mice, 2.5HIP nanoparticles prevented disease transfer by BDC-2.5 T cells and extended the survival of transplanted islet grafts. The tolerance worked through an IL-10-dependent mechanism, a natural immune-suppressing pathway. The protective effect involved increasing regulatory T cells in graft tissue, which limited the activity of dendritic cells—immune cells that normally trigger T-cell activation and autoimmune attack.

This approach represents a potential therapeutic strategy: using the very peptides that trigger autoimmunity as tolerogenic agents to suppress harmful immune responses. However, it is important to note that this research remains in preclinical stages and has not yet progressed to human clinical trials.

The identification of hybrid insulin peptides opens new avenues for understanding Type 1 diabetes pathogenesis. Because HIPs are elevated in at-risk and newly diagnosed patients, they may help researchers identify and stratify individuals at different stages of disease development.

The ability to convert HIP antigens into tolerogenic nanoparticles suggests a potential path toward immune-based therapies that could prevent or delay Type 1 diabetes onset. The next steps involve translating these findings from animal models to human studies to determine whether HIP-based tolerance strategies are safe and effective in people.

Source: Immunological reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.